Approval · Notice of Compliance 12588 · 2011
MINT-SIMVASTATIN: Notice of Compliance 12588
Issued August 29, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12588
- Date
- August 29, 2011
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Lipid Metabolism Regulator
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-SIMVASTATIN | 02372932 | Marketed |
| MINT-SIMVASTATIN | 02372940 | Marketed |
| MINT-SIMVASTATIN | 02372959 | Marketed |
| MINT-SIMVASTATIN | 02372967 | Marketed |
| MINT-SIMVASTATIN | 02372975 | Marketed |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB